Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?

  • Authors:
    • M Masutani
    • I Tsujino
    • T Fujie
    • M Yamaguchi
    • K Miyagi
    • T Yano
    • N Takahashi
    • Y Koya
    • T Horie
  • View Affiliations

  • Published online on: September 1, 1999     https://doi.org/10.3892/or.6.5.1045
  • Pages: 1045-1095
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Advanced non-small cell lung cancer (NSCLC) has proven to be remarkably resistant to standard chemotherapy regimens. One potential alternative approach is the use of dose-intensive chemotherapy with supportive therapy such as granulocyte-colony stimulating factor (G-CSF). We conducted a randomized study of dose-intensive cisplatin/vindesine/mitomycin C chemotherapy (DI-PVM) and standard cisplatin/vindesine/mitomycin C chemotherapy (PVM). A total of one hundred patients with III-IV NSCLC was randomized. The DI-PVM consisted of 3 cycles of cisplatin: 80 mg/m2 (day 1), vindesine: 3 mg/m2 (days 1 and 8) and mitomycin C: 8 mg/m2 (day 1) in 3-week intervals with concurrent G-CSF. The PVM consisted of 2 cycles of the same chemotherapy in 4-week intervals. Blood cell counts were checked twice a week, and G-CSF (2 microgram/kg, SC) was administered when the count was

Related Articles

Journal Cover

Sep-Oct 1999
Volume 6 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Masutani M, Tsujino I, Fujie T, Yamaguchi M, Miyagi K, Yano T, Takahashi N, Koya Y and Horie T: Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?. Oncol Rep 6: 1045-1095, 1999
APA
Masutani, M., Tsujino, I., Fujie, T., Yamaguchi, M., Miyagi, K., Yano, T. ... Horie, T. (1999). Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?. Oncology Reports, 6, 1045-1095. https://doi.org/10.3892/or.6.5.1045
MLA
Masutani, M., Tsujino, I., Fujie, T., Yamaguchi, M., Miyagi, K., Yano, T., Takahashi, N., Koya, Y., Horie, T."Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?". Oncology Reports 6.5 (1999): 1045-1095.
Chicago
Masutani, M., Tsujino, I., Fujie, T., Yamaguchi, M., Miyagi, K., Yano, T., Takahashi, N., Koya, Y., Horie, T."Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?". Oncology Reports 6, no. 5 (1999): 1045-1095. https://doi.org/10.3892/or.6.5.1045